Avonex PEN Satisfaction and Patients Experience Clinical Trial
NCT01366040 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89
Last updated 2013-09-16
Summary
This is an open-label, multicenter, survey-based study to determine subject satisfaction with using the single-use autoinjector for the delivery of AVONEX PS. Enrollment will consist of 200 subjects in a single cohort who have been prescribed AVONEX PEN in accord with its Product Monograph. All subjects must be experienced AVONEX PS users (i.e., using it for at least 12 weeks without any support person to help with the injections administered in the vastus lateralis) and enrolled in MS AllianceTM program (hereinafter, MS Alliance). The clinic nurse investigator will instruct the patient on the correct method of using AVONEX PEN and the first injection with Autoinjector, using the subject's own supply, will be completed in the clinic, with the clinic nurse investigator present. All further injections of AVONEX PEN will be self-administered at home. The subjects will complete the first set of questionnaires, including Subject Satisfaction Questionnaire, Ease of Use Grading Scale and the Autoinjector Instructions Grading Scale, within 10 minutes after the first injection at the clinic, and will be given another set of questionnaires to be completed at home within 10 minutes following the last study injection 2 months later, provided the subjects still continue to self-administer their AVONEX PEN. The first set of questionnaires will be left with the clinic nurse investigator to be sent to the CRO by fax or e-mail, while the second set will need to be mailed to the CRO by study subjects using the provided self-addressed, postage-paid envelope.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-30
- Primary Completion
- 2012-05-31
- Completion
- 2012-05-31
Countries
- Canada
Study Locations
More Related Trials
-
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
NCT01156298 ·Status: TERMINATED
-
Immunogenicity and Safety Study of Serum-Free Avonex
NCT00912860 ·Status: COMPLETED ·Phase: PHASE2
-
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
NCT00675883 ·Status: COMPLETED
-
Open-Label Safety Extension Study of Avonex
NCT00915460 ·Status: COMPLETED ·Phase: PHASE4
-
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
NCT00037102 ·Status: COMPLETED ·Phase: PHASE4
-
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
NCT02076841 ·Status: COMPLETED
-
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
NCT00784836 ·Status: TERMINATED ·Phase: PHASE3
-
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
NCT00168766 ·Status: COMPLETED ·Phase: PHASE4
-
AVONEX® Combination Trial - "ACT"
NCT00112034 ·Status: COMPLETED ·Phase: PHASE4
-
Avonex 15 Year Long Term Follow-up Study
NCT00525343 ·Status: COMPLETED
-
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
NCT00958009 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
NCT00986960 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
NCT05064436 ·Status: TERMINATED ·Phase: PHASE1
-
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
NCT00037115 ·Status: WITHDRAWN ·Phase: PHASE4
-
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT01093326 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00030966 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
NCT00324506 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
NCT00223301 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
NCT01864148 ·Status: COMPLETED ·Phase: PHASE2
-
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
NCT01272128 ·Status: COMPLETED
-
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
NCT00217295 ·Status: UNKNOWN ·Phase: PHASE2
-
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
NCT03560739 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
NCT00206648 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
NCT00292266 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886 ·Status: RECRUITING ·Phase: PHASE2